TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30683146
Drug: 1% simvastatin-acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% simvastatin-acid sodium salt ointment
Study: 30683146
Drug: 1% atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% atorvastatin calcium salt ointment
Study: 28454798
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 to 320 mg daily
Study: 26054142
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Zhuang medicine at Qineihuan point and conventional acupuncture
Study: 24060346
Drug: L‐NMMA (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (an unspecific nitric oxide synthase inhibitor)
Study: 24060346
Drug: Phenylephrine (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (an α‐adrenoceptor agonist)
Study: 20878646
Drug: Adjuvant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatments
Study: 19684412
Drug: Rigorous volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigorous volume management during thrice-weekly hemodialysis
Study: 17412579
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (1500 mg/day)
Study: 7946367
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Study: 7946367
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Study: 7946367
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (75 micrograms/hr)
Study: 7946367
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) fentanyl
Study: 3499244
Drug: Propofol (PROP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (PROP), 2.5 mg . kg‐1
Study: 3499244
Drug: Thiopentone (THIO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (THIO), 4 mg . kg‐1
Study: 3499244
Drug: Methohexitone (METH),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone (METH), 1.5 mg . kg‐1
Study: 28905874
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine transdermal patch (TNP)
Study: 28905874
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch (PBO)
Study: 16818281
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further donor cell infusion (group A)
Study: 12621795
Drug: Recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle-stimulating hormone (rFSH) 100 IU
Study: 12621795
Drug: Urinary follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary follicle-stimulating hormone (uFSH) 150 IU
Study: 2679204
Drug: Traditional mixed-sex
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional mixed-sex alcoholism treatment centers
Study: 29378998
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment applied to extraction sockets of the left third molars)
Study: 21205136
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon (PEG‐IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks
Study: 21205136
Drug: shorter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: shorter treatment (12‐16 weeks)
Study: 21205136
Drug: shorter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: shorter treatment (12‐16 weeks) in subgroup with RVR
Study: 21205136
Drug: prolonging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: prolonging therapy
Study: 17586189
Drug: Separate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate vaccines
Study: 17586189
Drug: DTaP-HepB-IPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-HepB-IPV plus Hib with PCV-7 administered 2 weeks later
Study: 15473622
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (BM) - hyperbaric bupivacaine 0.5% 2 mL + 1 mL of 2mg preservative‐free midazolam
Study: 15473622
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (B) - hyperbaric bupivacaine 0.5% 2 mL + saline 0.9% 1 mL
Study: 11303198
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronized 17 beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and thereafter 2 mg 17 beta‐estradiol combined with 10 mg dydrogesterone for a period of 3 months
Study: 9627593
Drug: Milk formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk formula (MF; 67 cal/100 ml)
Study: 28569520
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) focused on early change
Study: 25908506
Drug: Weight-loss intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-loss intervention + 2000 IU/day oral vitamin D3
Study: 25908506
Drug: Weight-loss intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-loss intervention + daily placebo
Study: 22682669
Drug: Chemotherapy-first strategy
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-first strategy
Study: 16678648
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 30 mg/d
Study: 16678648
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 40 mg/d
Study: 9416933
Drug: Extended-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release isosorbide mononitrate (ER-ISMN) 60 mg
Study: 9416933
Drug: Extended-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release isosorbide mononitrate (ER-ISMN) 120 mg
Study: 8279667
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration (exact dosage not specified)
Study: 8279667
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no alcohol, exact dosage not specified)
Study: 3300945
Drug: Peptichemio (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptichemio (1.2 mg/kg/d) for two 5-day courses; Group 2
Study: 3300945
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further antitumor therapy; Group 1
Study: 28586623
Drug: Follow-up survey
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up survey measuring vaccine hesitancy scores
Study: 28586623
Drug: Follow-up survey
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up survey measuring the proportion of vaccine hesitant mothers
Study: 19577829
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received the same care without reflexology therapy)
Study: 7988251
Drug: Immediate combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate combination chemotherapy (CAP)
Study: 7988251
Drug: Delayed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed combination chemotherapy (CAP)
Study: 2729939
Drug: Oral antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antacid (30 ml of aluminum hydroxide orally four times a day for 4 days)
Study: 30442233
Drug: Diet/Ca/D (cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet/Ca/D (cholecalciferol 50,000 IU/subject/week and calcium 1200 mg/dL/subject/day)
Study: 30442233
Drug: Diet/Ca (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet/Ca (calcium 1200 mg/dL/subject/day)
Study: 30442233
Drug: CON (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (no prescribed supplements)
Study: 24648723
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day, n=25)
Study: 24648723
Drug: No fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluoxetine (control group, n=25)
Study: 22198621
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea infusate (3 x 200 ml/day for 12 weeks)
Study: 20515467
Drug: Intravenous rehydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rehydration (IVR)
Study: 16146476
Drug: diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg x 3
Study: 10393606
Drug: Beclomethasone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone therapy
Study: 8930940
Drug: PD (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD (120 mg orally)
Study: 2034826
Drug: Isovolemic hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolemic hemodilution (15 ml/kg body weight) with lumbar epidural anesthesia
Study: 24501384
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG), once daily for 4 weeks
Study: 21963389
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (2×100 ml/d for 8 weeks)
Study: 21963389
Drug: Placebo (2×100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2×100 ml/d for 8 weeks)
Study: 29631782
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg oral daily)
Study: 11960396
Drug: All trans
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All trans retinoic acid (ATRA) 45 mg/m²/day from day 1 to complete remission combined with Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days.
Study: 11960396
Drug: Idarubicin 10
Normalized name: IDArubicin 10 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days without ATRA.
Study: 11960396
Drug: ATRA combined
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA combined with chemotherapy (Idarubicin and Cytarabine).
Study: 10190855
Drug: CD pedicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD pedicle screw implants
Study: 7577781
Drug: Blind standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind standard technique (group A: 8 mL bupivacaine 0.25%)
Study: 7577781
Drug: Ultrasonographic imaging
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonographic imaging technique (group B: 5 mL bupivacaine 0.25%)
Study: 2034479
Drug: HiFe (13.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiFe (13.8 mg elemental iron)
Study: 2034479
Drug: MidFe (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MidFe (7 mg elemental iron)
Study: 7326166
Drug: L(+) mepivacaine
Normalized name: L-(-)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L(+) mepivacaine
Study: 7326166
Drug: L(+) and
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L(+) and D(‐) mepivacaine
Study: 23557627
Drug: Hydrocortisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (20 mg bid for 10 days)
Study: 20499072
Drug: Calorie‐restricted legume‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie‐restricted legume‐based diet (L‐diet)
Study: 18282237
Drug: Community-wide azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Community-wide azithromycin treatment
Study: 16531164
Drug: Monophasic OC
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic OC containing 35 mug EE and 2 mg cyproterone acetate (CPA; n=10)
Study: 10895744
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine with fentanyl 1 microgram ml‐1
Study: 10895744
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine with fentanyl 2 micrograms ml‐1
Study: 10895744
Drug: Low-concentration/high-volume solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-concentration/high-volume solution
Study: 9561637
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation for 12 weeks
Study: 9561637
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation for 12 weeks
Study: 1532940
Drug: Domiciliary nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary nebulized fenoterol (F) 1.25 mg and ipratropium (I) 0.5 mg for three weeks
Study: 3157576
Drug: Zimeldine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimeldine (200 mg/day, increased to 300 mg/day after 7 days)
Study: 18407382
Drug: AS‐H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS‐H5N1 vaccine
Study: 18407382
Drug: Fluarix (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluarix (licensed seasonal influenza vaccine)
Study: 15206667
Drug: Olanzapine at
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine at >16 mg
Study: 15206667
Drug: Risperidone at
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone at 4 mg
Study: 15206667
Drug: Ziprasidone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone at 120 mg
Study: 15206667
Drug: Risperidone at
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone at 2 mg daily
Study: 15206667
Drug: Olanzapine at
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine at 6 mg
Study: 15206667
Drug: Aripiprazole at
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole at 10 mg daily
Study: 15206667
Drug: Clozapine above
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine above 400 mg
Study: 15206667
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at 3.3 to 10 mg
Study: 15206667
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of haloperidol
Study: 15206667
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of FGAs
Study: 11388531
Drug: Epidural lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural lidocaine (15 ml; 2%) with intravenous saline placebo
Study: 11388531
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1 mg/kg bolus dose; 25 microg x kg(‐1) x min(‐1))
Study: 11388531
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone (intravenous saline placebo)
Study: 9253321
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium lactate, 500 mg/day)
Study: 8390368
Drug: metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 20 mg
Study: 8390368
Drug: saline 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 20 ml
Study: 3829698
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of PTGG and steroid subconjunctival injection
Study: 3829698
Drug: Steroid subconjunctival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid subconjunctival injection alone
Study: 3829698
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of PTGG alone
Study: 29772657
Drug: Optimized Virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized Virgin Olive Oil (OVOO) (490 ppm of phenolic compounds and 86 ppm of triterpenes)
Study: 29772657
Drug: Virgin Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin Olive Oil (VOO) (124 ppm of phenolic compounds and 86 ppm of triterpenes)
Study: 29772657
Drug: Functional Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Olive Oil (FOO) (487 ppm of phenolic compounds and 389 ppm of triterpenes)
Study: 29772657
Drug: Virgin Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin Olive Oil (VOO) with at least 124 ppm of phenolic compounds
Study: 27400272
Drug: 80mg atorvastatin
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg atorvastatin
Study: 19958646
Drug: Magnesium isoglycyrrhizinate
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium isoglycyrrhizinate 100 mg once daily (group A)
Study: 19958646
Drug: Magnesium isoglycyrrhizinate
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium isoglycyrrhizinate 150 mg once daily (group B)
Study: 19958646
Drug: Compound glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound glycyrrhizin 120 mg once daily (group C)
Study: 15727954
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and steroidogenic inhibitor
Study: 11990404
Drug: One additional
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One additional daytime 2-L exchange (intervention group)
Study: 8134073
Drug: Metoclopramide regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide regimen (2 mg/kg IV every 2 hours x 3)
Study: 8134073
Drug: Ondansetron regimen
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron regimen (0.15 mg/kg IV every 4 hours x 3)
Study: 2643902
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 micrograms twice a day)
Study: 24028597
Drug: Opalescence Boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opalescence Boost PF 40% gel
Study: 21174144
Drug: H5N1 vaccine
Normalized name: Influenza H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 vaccine with AS03(A)
Study: 21174144
Drug: H5N1 vaccine
Normalized name: Influenza H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 vaccine without AS03(A)
Study: 19581353
Drug: Salmeterol/Fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone combination (SFC) (SAL 50 microg/FP 500 microg)
Study: 19581353
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Placebo, SAL, FP, SFC)
Study: 17356088
Drug: Herbst mandibular
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbst mandibular advancement splint (MAS) treatment for 1 year
Study: 15094948
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement with synbiotics (PS)
Study: 15094948
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement without synbiotics (P)
Study: 9256938
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and Saquinavir (combination)
Study: 10385495
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily for 6 weeks
Study: 8682968
Drug: 2% minoxidil
Normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minoxidil topical solution
Study: 31307412
Drug: ML program
Normalized name: 0.4 ML Program 100 MG/ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML program (10-week group sessions focusing on evidence-based parenting practices followed by the MINISTOP application for 6 months)
Study: 23506324
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of a vest during medication administration
Study: 21153900
Drug: Dietary group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary group (DG) receiving daily for 30 months, 1,200 mg of calcium and 7.5 μg of vitamin D(3) for the first 12 months, increasing to 22.5 μg for the remaining 18 months through fortified dairy products
Study: 19618698
Drug: Dual-target condition
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-target condition (caregiver intervention + care recipient treatment)
Study: 12153607
Drug: Ghrelin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (1.0 micro g/kg i.v. at 0 min)
Study: 12153607
Drug: GHRH (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1.0 micro g/kg i.v. at 0 min)
Study: 12153607
Drug: OGTT (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGTT (100 g oral glucose at -45 min)
Study: 12153607
Drug: Li-He (Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Li-He (Intralipid 10% 250 ml + heparin 2500 U i.v. from -30 to +120 min)
Study: 12153607
Drug: ARG (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARG (0.5 g/kg infused from 0 to +30 min)